Discussion
Although we used two methods to determine acetylator status, Evans6 had shown that these gave identical separation. We also felt that it was valid to compare our data with his population survey data. In our series slow acetylators were less common among diabetics who had had the disease for at least 10 years without developing neuropathy than among those with neuropathy or the normal population. An increased proportion of fast acetylators was reported, in a series of unselected diabetics, but in our series the preponderance of fast acetylators was seen only in the group without neuropathy. The difference between the two groups of diabetics makes it unlikely that this preponderance was due merely to linkage between acetylator and putative diabetic genes. Nor could there be a relation with the histocompatibility genes, since there was a similar distribution of acetylator phenotypes between patients with juvenile-onset and maturity-onset diabetes, yet HLA-B8, BW15, and BW18 are increased in frequency only in juvenile-onset diabetes.6
The association between freedom from neuropathy and fast acetylator phenotype was similar to that found in patients taking isoniazid.-In isoniazid neuropathy, however, axonal degeneration is the main pathological lesion,9 whereas in diabetes segmental demyelination is usually seen.10 Hence the two neuropathies are unlikely to have a common aetiology, such as pyridoxine deficiency. Recently, however, axonal degeneration was reported in experimental diabetic neuropathy."1 Our findings suggest that genetic factors unrelated to the diabetic diathesis may interact with the metabolic abnormality of diabetes to determine whether a patient develops a neuropathy. Clearly the impaired ability to acetylate may have aetiological significance. 
Summary
The Medical Research Council's trial of BCG and vole bacillus vaccines in the prevention of tuberculosis in Great Britain has ended after 20 years' follow-up of the 54 239 participants, who were aged 14 to 15 years when they entered the trial in 1950-2. Participants who were tuberculin positive on entry were left unvaccinated; those who were tuberculin negative were allocated at random to an unvaccinated or to a vaccinated group.
The protective efficacy of each of the two vaccines, among those initially tuberculin negative, was 84% during the first five years, and gradually decreased, averaging 77% for each vaccine over the whole period. The four reports already publishedl-4 gave further details of the trial and showed that the two vaccines conferred substantial protection against tuberculosis for 15 years after vaccination. This paper is intended only as a supplement to those reports; it extends the information on protection up to 20 years after vaccination, at which stage the trial ended.
Cases of tuberculosis developing 15 to 20 years after entry Information on definite and suspected cases of tuberculosis in the trial participants continued to be obtained from regular returns made by chest clinics and medical officers of health throughout Great Britain. Experience had shown that the annual postal inquiries to individual participants, which had been made in parallel with the chest clinic and local health authority returns for the previous seven years, had detected only a few cases of tuberculosis (all non-respiratory) that were not included in the returns-about one case a year. 4 The cases of respiratory tuberculosis recorded among trial participants from 15 to 20 years are thus believed to represent a complete total, though a very few cases of non-respiratory tuberculosis may have escaped notice.
As before, the case records of all patients with tuberculosis or suspected tuberculosis or with a persistent pulmonary radiographic abnormality which came to notice during the period were submitted to an independent assessor who was kept unaware of the results of any tuberculin tests and of whether or not vaccination had been performed. The assessment was made from the -series of radiographs and the findings of all the clinical and other examinations of the patient, both on diagnosis and subsequently.
Twenty-seven participants were found to have developed tuberculosis from 15 to 20 years after entry. Of these 17 had pulmonary tuberculosis and two had pleural effusions without evidence of pulmonary tuberculosis. The eight participants with non-respiratory disease comprised five with genitourinary tuberculosis, two with tuberculous adenitis, and one with a tuberculous ethmoid.
The 
The numbers of cases of genitourinary tuberculosis in the four fiveyear periods (not separately tabulated) were 3, 5, 14, and 5, and of these 3, 4, 9, and 2 respectively occurred among participants who were already positive to 3 TU on entry to the trial. The incidence of this form of tuberculosis thus fell from the peak which it showed 10 to 15 years after entry-that is, when the participants were aged 25-29 years.
Incidence of tuberculosis during the 20 years
The annual incidence of tuberculosis in each of the trial groups is shown in table II. For the whole period the average annual incidence was 0 98 per 1000 in the tuberculin negative unvaccinated group and 0 23 per 1000 in each vaccinated group. The protective efficacy (the percentage reduction in incidence in the vaccinated group compared with that in the randomly established unvaccinated group) was thus 77 00 for each of the two vaccines. In those participants with large positive reactions to 3 TU initially (15 mm or more) the average annual incidence during the period was 1 04 per 1000, which was substantially larger than the incidence of 0 45 per 1000 that was found both in those with smaller positive reactions to 3 TU (5-14 mm) and in thosewho were positive only to 100 TU. Table II also shows the incidence in each trial group in successive five-year periods. The incidences in the tuberculin-negative unvaccinated group were 2 50, 1 06, 0 26, and 0-08 per 1000, compared with 0 40, 0-34, 0 09, and 0-07 respectively for the two vaccinated groups combined. The protective efficacy of vaccination thus showed a progressive decrease in successive five-year periods. The efficacy of 9 % from 15 to 20 years after vaccination cannot be regarded as a precise estimate, being based on totals of only five cases of tuberculosis in the negative unvaccinated group and seven in the vaccinated groups combined. The downward trend in protective efficacy during the trial was, however, significant at the 1 % level for both vaccines combined and for BCG vaccine separately. Among those with large positive reactions to 3 TU initially, the incidences of cases of tuberculosis in successive five-year periods were 2 79, 0 71, 0 48, and 0 15 per 1000 participants. The high early incidence of tuberculosis in this group and the subsequent decrease were noted and discussed in the second report.2 Among those with smaller positive reactions to 3 TU and those positive only to 100 TU the incidence during the first five years was about a third of that in subjects with large positive reactions to 3 TU and remained lower, though the differences diminished considerably. In the final five-year period the incidence was very low in all the three initially positive groups, though still higher than in the three initially negative groups.
Discussion
A full commentary on the results of the trial during the first 15 years was included in the fourth report.4 We present here a postscript to that commentary, in the light of the figures during the whole 20-year period.
This trial has shown clearly that in Great Britain the use of BCG vaccine and vole bacillus vaccine, given as artificial immunising agents in 1950-2 to adolescents aged about 15 years, led to a substantial reduction in the incidence of tuberculosis which extended over the whole of the ensuing 20 years. The reduction, among those who were uninfected with tubercle bacilli initially, was about 75 to 80",, with each vaccine.
There was a decrease in the incidence of tuberculosis during the 20 years in all trial groups, especially among those who initially gave negative results to a tuberculin test. In this group the peak incidence occurred two and a half to five years after entry-that is, in about 1955, when the participants were aged 18 years. With the diminishing risk of tuberculosis infection and the increasing age of the cohort the number of cases in this trial group approximately halved in each successive two and a half year period. If this trend has continued beyond 20 years then only one or at most two cases of tuberculosis will have developed among more than 12 000 initially uninfected and unvaccinated subjects from 20 to 25 years after entry to the trial. The continuance of the trial beyond 20 years would thus have provided zirtually no more information on the benefit from tuberculosis jaccination, so the trial was ended.
The gradual convergence of the tuberculosis rates in the negative unvaccinated and the vaccinated groups as the trial proceeded has been confirmed by the figures in the present report. The reasons were discussed fully previously.'3 4Briefly, the convergence could have resulted from (a) a gradual increase in the level of resistance in the unvaccinated group (relative to the vaccinated groups) as a result of natural infections by tubercle bacilli and other mycobacteria, or the withdrawal of those particularly susceptible because they contracted tuberculosis; (b) a gradual decrease in the level of resistance in the vaccinated groups (relative to the unvaccinated group) as a result of a waning in the efficacy of the vaccines; or (c) the operation of both effects. Whatever the full explanation for the convergence may be, the very considerable initial benefit conferred by vaccination has clearly not been maintained. It is unfortunate that the information now available from 15 to 20 years is too limited to provide a reliable estimate of the extent of the benefit during this final period.
Since the publication of the fourth report 20-year reports on two of the United States Public Health Service trials of BCG vaccination have appeared. 5 6 In North America also the already low incidence of tuberculosis has decreased further, and these reports do not substantially alter the previous findings. There have been several commentaries4 7-9 on the reasons for the wide differences in the efficacy of BCG vaccination found in these and other trials.
In Great Britain surveillance studies'0" have been made of the efficacy of BCG vaccination in the national scheme for children aged 10-13 years. These studies were not controlled trials but were comparisons of the incidence of tuberculosis in subjects given BCG vaccine in the national scheme and in those who did not participate. They provided supporting evidence of the continuing efficacy of BCG vaccine in preventing tuberculosis in Great Britain, notwithstanding the variations found in other parts of the world. In particular, they showed the high protective efficacy in this country of vaccine from the Glaxo strain of BCG (which was derived from the Copenhagen strain of BCG used in the Medical Research Council trial); the Glaxo strain is now used routinely for BCG vaccination in this country and in many others.
Nevertheless, the expected benefit to the section of the community covered by a tuberculosis vaccination scheme (in adolescence or at any other age) does not depend solely on the efficacy of the vaccine in those who are vaccinated. The benefit may be expressed as the absolute reduction in incidence of tuberculosis in the entire population group considered for vaccination, as a result of vaccinating those who are eligible. This is the product of three factors4 ': (a) the protective efficacy of the vaccine among those who are eligible-that is, those who give a negative reaction to tuberculin; (b) the expected annual incidence of tuberculosis in those eligible if they were left unvaccinated; and (c) the proportion of the population who are eligible. The second factor is the most important determinant of the degree of expected benefit.
The prevalence and incidence of tuberculosis in this country have decreased radically since the national scheme for BCG vaccination at the age of 10-13 years was introduced in 1953. The decreasing risk of tuberculous infection has led to an increase in the proportion of children who are eligible to benefit, but this has been more than offset by the very substantial decrease in the incidence of tuberculosis in adolescents and young adults. Thus despite the continuing high efficacy of BCG vaccination, the benefit to be expected from the national scheme is now far less than it was in 1953 and, if the incidence of tuberculosis continues to decline, will decrease still further. Recent studies'""-3 have sought to estimate not only the present and future benefits from the national scheme but also its costs (in the widest sense) to provide a rational basis for deciding how much longer large-scale routine BCG vaccination at the age of 10-13 should continue in Great Britain.
